INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
06/10/2026
Back to search
Official data from USPTO
AYOXXA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
06/11/2026
Trademark type
Word
Nice classes
5
Filing date
10/06/2017
Registration date
03/26/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/10/2025
Last transaction
06/11/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DE
Examiner
BERLIN, JUSTIN E
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
AyoxxA Biosystems GmbH
Representatives
Joyce von Natzmer Agris & von Natzmer LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposesfor treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; chemical and biochemical reagents for medical purposes; chemical and biochemical preparations for veterinary purposesfor treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations; chemical and biochemical reagents for veterinary purposes; chemical and biochemical preparations for pharmaceutical purposesfor treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; chemical and biochemical reagents for medical or veterinary pharmaceutical purposes; biological agents for laboratory analyses for medical purposespeptidesproteins and nucleic acids used as diagnostic agents for medical purposes; biological agents for laboratory analyses for veterinary purposespeptidesproteins and nucleic acids used as diagnostic agents for veterinary purposes; chemical and biochemical preparations and reagents for medical purposesfor use in DNA analyses; chemical and biochemical preparations for blood tests for medical purposes; chemical and biochemical reagents for blood tests for medical purposes; chemical and biochemical preparations for blood tests for veterinary purposes; chemical and biochemical reagents for blood tests for veterinary purposes; peptidesproteinsnucleic acids and other biomoleculescomplexes of these moleculesfor medical purposessynthetic or natural peptidesproteinsallergensmetabolites or nucleic acids for the treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseasesprotein arrays for medical diagnosis purposesnucleic acid sequences for medical diagnosis purposes; proteinsnucleic acids and other biomoleculescomplexes of these moleculesfor veterinary purposessynthetic or natural peptidesproteinsallergensmetabolites or nucleic acids for treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations in animalsprotein arrays for veterinary diagnosis purposesnucleic acid sequences for veterinary diagnosis purposes; chemical and biochemical preparations and reagents for labelling of molecules for medical detection and monitoring purposes; chemical and biochemical preparations and reagents for labelling of molecules for veterinary detection and monitoring purposes
Publications
History of USPTO decisions and trademark events.
29 publications found
C71T
CANCELLED SECTION 71
10/10/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/26/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/01/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/16/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/25/2019
FIMP
FINAL DISPOSITION PROCESSED
07/25/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/26/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
03/26/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/08/2019
PUBO
PUBLISHED FOR OPPOSITION
01/08/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/19/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/14/2018
DOCK
ASSIGNED TO EXAMINER
10/22/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/21/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/21/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2018
RFNP
REFUSAL PROCESSED BY IB
04/06/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/22/2018
RFRR
REFUSAL PROCESSED BY MPU
03/22/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/22/2018
CNRT
NON-FINAL ACTION WRITTEN
03/21/2018
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
02/16/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/07/2018
CNRT
NON-FINAL ACTION WRITTEN
02/06/2018
DOCK
ASSIGNED TO EXAMINER
01/16/2018
MAFR
APPLICATION FILING RECEIPT MAILED
01/16/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/04/2018
Continuous trademark protection
Get notified about every new filing that threatens AYOXXA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.